HK1060280A1 - Reducing side effects of chemotherapy in cancer patients - Google Patents

Reducing side effects of chemotherapy in cancer patients

Info

Publication number
HK1060280A1
HK1060280A1 HK03109035A HK03109035A HK1060280A1 HK 1060280 A1 HK1060280 A1 HK 1060280A1 HK 03109035 A HK03109035 A HK 03109035A HK 03109035 A HK03109035 A HK 03109035A HK 1060280 A1 HK1060280 A1 HK 1060280A1
Authority
HK
Hong Kong
Prior art keywords
chemotherapy
side effects
cancer patients
reducing side
reducing
Prior art date
Application number
HK03109035A
Other languages
English (en)
Inventor
Alfred R Rudolph
Vincent Chung-Yin Tam
Maggie Jie Quan
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of HK1060280A1 publication Critical patent/HK1060280A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
HK03109035A 2000-05-01 2003-12-11 Reducing side effects of chemotherapy in cancer patients HK1060280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,917 US6462017B1 (en) 2000-05-01 2000-05-01 Method of reducing side effects of chemotherapy in cancer patients
PCT/US2001/012696 WO2001082949A2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Publications (1)

Publication Number Publication Date
HK1060280A1 true HK1060280A1 (en) 2004-08-06

Family

ID=24244042

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03109035A HK1060280A1 (en) 2000-05-01 2003-12-11 Reducing side effects of chemotherapy in cancer patients

Country Status (10)

Country Link
US (1) US6462017B1 (xx)
EP (1) EP1357935B1 (xx)
JP (1) JP2004501870A (xx)
CN (1) CN100441221C (xx)
AT (1) ATE348630T1 (xx)
AU (2) AU2001255475B2 (xx)
CA (1) CA2407238C (xx)
DE (1) DE60125417D1 (xx)
HK (1) HK1060280A1 (xx)
WO (1) WO2001082949A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05417B1 (et) * 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
AU2003295838B2 (en) 2002-11-25 2008-05-22 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
JP5044150B2 (ja) * 2005-08-05 2012-10-10 Ｔｏｔｏ株式会社 光照射により薬効を消失させる医薬二酸化チタン複合材
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
WO2008119032A1 (en) * 2007-03-27 2008-10-02 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
CA2708168A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP3028743A3 (en) * 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Compositions for mucositis and oncology therapies
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
EP3878462A1 (en) * 2015-10-29 2021-09-15 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of cancer radiotherapy
CN107137684A (zh) * 2017-05-23 2017-09-08 山西中医学院 一种用于胃肠疾病的药物组合物及其制备方法和用途
FR3074042A1 (fr) 2017-11-29 2019-05-31 Galderma Research & Development Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN109820859A (zh) * 2019-04-09 2019-05-31 上海市计划生育科学研究所 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527393A (en) * 1894-10-09 Busy-test for multiple switchboards
US5273963A (en) 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Also Published As

Publication number Publication date
AU5547501A (en) 2001-11-12
CA2407238A1 (en) 2001-11-08
EP1357935B1 (en) 2006-12-20
CN1529614A (zh) 2004-09-15
WO2001082949A9 (en) 2004-04-22
CA2407238C (en) 2012-03-13
DE60125417D1 (de) 2007-02-01
EP1357935A2 (en) 2003-11-05
WO2001082949A2 (en) 2001-11-08
WO2001082949A3 (en) 2003-08-28
CN100441221C (zh) 2008-12-10
JP2004501870A (ja) 2004-01-22
ATE348630T1 (de) 2007-01-15
US6462017B1 (en) 2002-10-08
AU2001255475B2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
HK1060280A1 (en) Reducing side effects of chemotherapy in cancer patients
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
RS20050975A (xx) Sredstva za specifično vezivanje faktora rasta hepatocita
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
TW200718689A (en) 2-Amino-quinazolin-5-ones
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
SI1297013T1 (sl) Uporaba TACI kot protitumorskega sredstva
UA87877C2 (xx) Пегильований ліпосомальний доксорубіцин в комбінації з ектеїнасцидином 743 (ecteinescidin 743)$пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
EP2020237A3 (en) Ceramide and chemotherapeutic agents for inducing cell death
DE60227244D1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
ES2189059T3 (es) Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
BR0301701A (pt) Método para prevenir a diminuição de uma quantidade de leite de mama em um mamìfero
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
WO2008122794A3 (en) Breast cancer methods, medicaments and agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130419